Literature DB >> 12633984

Fluorescence contrast and threshold limit: implications for photodynamic diagnosis of basal cell carcinoma.

Marica B Ericson1, Carin Sandberg, Fredrik Gudmundson, Arne Rosén, Olle Larkö, Ann-Marie Wennberg.   

Abstract

This study was designed to evaluate what application time of delta-5-aminolaevulinic acid (ALA) results in highest contrast between tumour and normal skin, in the interval 1-4 h, when using photodynamic diagnosis (PDD) of basal cell carcinomas (BCC) located on the face. Moreover, a value of the demarcation limit has been derived based on the fluorescence variation in normal skin adjacent to the tumour. Forty patients were included in the study, randomly allocated to four different groups with varying ALA application time in the range 1-4 h. The contrast, defined as the ratio between the fluorescence intensity in ALA-treated tumour tissue and normal skin, was calculated for each patient, and the mean values in each group were evaluated as a function of ALA application time. In addition, the fluorescence intensity variation in ALA-treated normal skin adjacent to the tumour was assessed. The results from this study show a peak of the mean contrast values after 3 h ALA application, but due to large interpatient variation, the mean contrast did not differ significantly in the interval 2-4 h. After 2 h ALA application, the fluorescence intensity variation in the normal ALA-treated skin was found to be at a maximum, which suggests that 2 h ALA application is not preferable when using PDD. Based on data of the fluorescence variation in ALA-treated normal skin after 3 and 4 h ALA application, a tolerance interval was calculated implying that values above 1.4 times the mean normal fluorescence indicate an abnormal condition. This tolerance limit agrees well with results obtained in a former study. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12633984     DOI: 10.1016/s1011-1344(02)00413-x

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  6 in total

Review 1.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses.

Authors:  Allison Marrero; Theresa Becker; Ulas Sunar; Janet Morgan; David Bellnier
Journal:  Photochem Photobiol       Date:  2011-06-13       Impact factor: 3.421

Review 3.  Recent advances in the prevention and treatment of skin cancer using photodynamic therapy.

Authors:  Baozhong Zhao; Yu-Ying He
Journal:  Expert Rev Anticancer Ther       Date:  2010-11       Impact factor: 4.512

4.  Neoadjuvant use of photodynamic therapy in Basal cell and squamous cell carcinomas of the face.

Authors:  Goran Jeremic; Corey C Moore; Michael G Brandt; Philip C Doyle
Journal:  ISRN Dermatol       Date:  2011-05-31

5.  Use of Protoporphyrin Fluorescence to Determine Clinical Target Volume for Non-melanotic Skin Cancers Treated with Primary Radiotherapy.

Authors:  Stephanie Casey; Lara Best; Olga Vujovic; Kevin Jordan; Barbara Fisher; Deborah Carey; Deborah Bourdeau; Edward Yu
Journal:  Cureus       Date:  2016-09-04

6.  Review of photodynamic therapy in actinic keratosis and basal cell carcinoma.

Authors:  Marica B Ericson; Ann-Marie Wennberg; Olle Larkö
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.